Old Web
English
Sign In
Acemap
>
Paper
>
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA
IBRUTINIB TOLERABILITY AND OUTCOME IN PATIENTS WITH HIGH‐RISK CHRONIC LYMPHOCYTIC LEUKEMIA
2021
Adalgisa Condoluci
L. Terzi‐di‐Bergamo
Gabriela Forestieri
Riccardo Moia
Clara Deambrogi
Marina Deodato
Anna Maria Frustaci
Michele Merli
R. Mattarucchi
Francesco Autore
G Fahrni
Lydia Scarfò
D. Gussetti
Pietro Bulian
A. Zanatta
Valeria Spina
Martin Faderl
Alessio Bruscaggin
K. Pini
D. Piffaretti
Ricardo Koch
Maria Cristina Pirosa
M G Cittone
Jacob Passweg
Franco Cavalli
E. Zucca
Bernhard Gerber
Silke Gillessen
Georg Stussi
V. Gattei
Paolo Ghia
Michael Gregor
Luca Laurenti
Francesco Passamonti
Alessandra Tedeschi
Gianluca Gaidano
D. Rossi
Keywords:
Internal medicine
Ibrutinib
in patient
Chronic lymphocytic leukemia
Outcome (game theory)
Oncology
Medicine
Tolerability
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]